A Phase Ib Study of Chemoimmunotherapy with Pegylated Liposomal Doxorubicin and Pembrolizumab in Estrogen Receptor-Positive Metastatic Breast Cancer. | ClinicLe

Pegylated liposomal doxorubicin (PLD) is a potent immunogenic cell death inducer, allowing for improved tumor-immune recognition and T-cell activation. We report a phase Ib study of combined PLD and pembrolizumab (PEM) in estrogen receptor (ER)-positive/human epidermal growth fac

Medical Literature · Updated 2026-08-07

← Back to articles

This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.